research use only
Cat.No.S8915
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Fatty Acid Synthase Inhibitors | Denifanstat (TVB-2640) Fatostatin TVB-3664 C75 Betulin FT113 Desoxyrhaponticin Sodium palmitate Praeruptorin B trans-Chalcone |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| MA104 | Antiviral assay | 24 hrs | Antiviral activity against Rotavirus SA11 in MA104 cells assessed as inhibition of viral replication after 24 hrs by immunofluorescent assay and Western blotting analysis, ED50 = 21.2 μM. | 22365411 | ||
| MA104 | Cytotoxicity assay | 24 hrs | Cytotoxicity against monkey MA104 cells after 24 hrs, TD50 = 28.5 μM. | 22365411 | ||
| A375 | Function assay | Inhibition of FASN in human A375 cells, IC50 = 32.43 μM. | 21726077 | |||
| KB | Cytotoxicity assay | Cytotoxicity in human KB cells, IC50 = 36.5 μM. | 21504156 | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 51 mg/mL
(200.53 mM)
Ethanol : 26 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 254.32 | Formula | C14H22O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 191282-48-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | trans-C75, (±)-C75 | Smiles | CCCCCCCCC1C(C(=C)C(=O)O1)C(=O)O | ||
| Targets/IC50/Ki |
FASN
(clonogenic assay) 35 μM
FASN
(spheroid growth assay) 50 μM
|
|---|---|
| In vitro |
C75 is toxic to prostate cancer cells. C75 reduces cell migration, while enhances radiation-induced clonogenic kill and enhances the spheroid growth delay induced by radiation exposure. Apoptosis induction by radiation exposure is enhanced by C75 treatment. C75 inhibits fatty acid synthesis and growth of established cancer cell lines from neu-N transgenic mice. C75 reduces the proliferation and expression of FAS, neu, and related genes in mammary epithelium. |
| In vivo |
C75 inhibits fatty acid synthesis and in vivo mammary cancer development. C75 treatment prevents mammary cancer development and retards mammary development in neu-N transgenic mice. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.